Impact of life-sustaining therapies on critically ill patients with cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text component.
The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results